Persistent concerns that Alphabet Inc. has fallen behind in the artificial intelligence supremacy race has weighed on the ...

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...

NVIDIA will be the first industry partner to adopt SynthID, a Google DeepMind AI technology that embeds digital watermarks ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict the shape of not only proteins but also DNA, RNA and other biological ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet, according to the Financial Times. The AI-first drug design and ...

U.S. tech titans Apple (AAPL) and Alphabet (GOOGL) are reportedly among other major names in talks with Japanese ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

Alphabet's forward P/E is historically low and 28.11% below Nasdaq's, making it an attractive buy at current levels. Click ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue on its mission to create new drugs and medicines using AI.

Houlihan Financial Resource Group Ltd. decreased its position in Alphabet Inc. (NASDAQ:GOOGL – Free Report) by 2.2% during ...

Lynx Investment Advisory increased its stake in Alphabet Inc. (NASDAQ:GOOGL – Free Report) by 1.3% in the 4th quarter, ...